13d
Sourcing Journal on MSNRelay Technologies Bags $35M Series A for Tech-Enabled E-Commerce DeliveryThe European startup wants to decrease the time-and the number of miles-it takes to deliver parcels to consumers.
Hosted on MSN1mon
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stockFollowing these transactions, the trust retains 199,548 shares of Relay Therapeutics. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 18.4x.
An example is how Relay has streamlined operations to extend its cash runway. A 15% workforce reduction and R&D prioritization resulted in $50 million in expected annual savings for the company.
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events ...
Relay Therapeutics (NASDAQ:RLAY – Get Free Report) had its price objective decreased by equities researchers at Stifel ...
Founded by CEO Jonathan Jenssen and COO Nicole Mazza, who both previously worked at last-mile delivery company Stuart, Relay is now clearly entering its AI-driven scale-up phase. Most delivery ...
The buck stops at truck stops when using this company’s anti-fraud app Relay Payments, which is digitizing truck stop transactions, is one of Fast Company's Most Innovative Companies in logistics.
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, Ratings reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results